<DOC>
	<DOCNO>NCT01720446</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial evaluate cardiovascular long-term outcome semaglutide subject type 2 diabetes . The trial event-driven , i.e . maximum trial duration ( max . 148 week ) depend accrual major adverse cardiovascular event ( MACE ) trial remain research programme . The incidence MACE monitor throughout trial terminate accord plan pre-specified stop criterion meet .</brief_summary>
	<brief_title>Trial Evaluate Cardiovascular Other Long-term Outcomes With Semaglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Men woman type 2 diabetes mellitus Age equal 50 year screen clinical evidence cardiovascular disease age equal 60 year screen subclinical evidence cardiovascular disease Antidiabetic drug na√Øve , treat one two oral antidiabetic drug ( OADs ) , treat human Neutral Protamin Hagedorn ( NPH ) insulin longacting insulin analogue premixed insulin , type insulin either alone combination one two OADs HbA1c equal 7.0 % screen Type 1 diabetes mellitus Use glucagonlike peptide1 ( GLP1 ) receptor agonist ( exenatide , liraglutide , ) pramlintide within 90 day prior screen Use dipeptidyl peptidase 4 ( DPPIV ) inhibitor within 30 day prior screen Treatment insulin basal premixed insulin within 90 day prior screen except shortterm use connection intercurrent illness Acute decompensation glycaemic control require immediate intensification treatment prevent acute complication diabetes ( eg diabetes ketoacidosis ) within 90 day prior screen History chronic pancreatitis idiopathic acute pancreatitis Acute coronary cerebrovascular event within 90 day prior randomisation Currently plan coronary , carotid peripheral artery revascularisation Chronic heart failure New York Heart Association ( NYHA ) class IV Personal family history multiple endocrine neoplasia type 2 ( MEN2 ) familial medullary thyroid carcinoma Personal history nonfamilial medullary thyroid carcinoma Screening calcitonin equal 50 ng/L</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>